**Manuscripts in preparation**

Robert J. Paproski, Desmond B. Pink, Deborah L. Sosnowski, Catalina Vasquez, John D. Lewis. “Building Predictive Disease Fingerprints using Extracellular Vesicle Microflow Cytometry and Machine Learning.”

Maria Cutumisu, Catalina Vasquez, Maxwell Uhlich, Perrin H Beatty, Homeira Hamayeli Mehrabani, Rume Djebah, Albert Murtha, Russell Greiner, John D. Lewis. “Introducing PROSPeCT: A Predictive Research Online System for Prostate Cancer Tasks.”

Adrian Fairey, Robert J Paproski, Desmond Pink, Deborah Sosnowski, Catalina Vasquez, Bryan Donnelly, Eric Hyndman, Armen Aprikian and John D Lewis. “Clinical analysis of the Extracellular Vesicle Fingerprint blood test to refine the prediction of clinically-significant prostate cancer.”

Vasquez C, Kolinsky M, Djebah R, and Lewis JD.  **“**Driving the clinical translation of innovative technologies to improve prostate cancer patient outcomes with the Alberta Prostate Cancer Registry and Biorepository.”

Choi-Fong Cho, Laura Fung, Tienabe K. Nsiama, Daniela F. Quail, Desmond Pink, Alisha Kadam, Katia Carmine-Simmen, Deborah Sosnowski, Lynne M. Postovit, Leonard G. Luyt, John D. Lewis*.* “E7C13, an EGFL7-derived peptide as a potent angiogenesis inhibitor.”

Pink DB, Paproski RJ, Vasquez C, et al: A novel extracellular vesicle blood test to distinguish indolent and aggressive prostate cancer at diagnosis.

**Publications 2017-2018**

Abou-Ouf, H., M. Alshalalfa, M. Takhar, N. Erho, B. Donnelly, E. Davicioni, R. J. Karnes and T. A. Bismar (2018). "Validation of a 10-gene molecular signature for predicting biochemical recurrence and clinical metastasis in localized prostate cancer." Journal of Cancer Research and Clinical Oncology 144(5): 883-891.

Athanazio, D., G. Gotto, M. Shea-Budgell, A. Yilmaz and K. Trpkov (2017). "Global Gleason grade groups in prostate cancer: concordance of biopsy and radical prostatectomy grades and predictors of upgrade and downgrade." Histopathology 70(7): 1098-1106.

Bismar, T. A., S. Hegazy, Z. Feng, D. Yu, B. Donnelly, N. Palanisamy and B. J. Trock (2018). "Clinical utility of assessing PTEN and ERG protein expression in prostate cancer patients: a proposed method for risk stratification." Journal of Cancer Research and Clinical Oncology 144(11): 2117-2125.

Bouvet, V., M. Wuest, J. J. Bailey, C. Bergman, N. Janzen, J. F. Valliant and F. Wuest (2017). "Targeting Prostate-Specific Membrane Antigen (PSMA) with F-18-Labeled Compounds: the Influence of Prosthetic Groups on Tumor Uptake and Clearance Profile." Molecular Imaging and Biology 19(6): 923-932.

Catton, C. N., H. Lukka, C.-S. Gu, J. M. Martin, S. Supiot, P. W. M. Chung, G. S. Bauman, J.-P. Bahary, S. Ahmed, P. Cheung, K. H. Tai, J. S. Wu, M. B. Parliament, T. Tsakiridis, T. B. Corbett, C. Tang, I. S. Dayes, P. Warde, T. K. Craig, J. A. Julian and M. N. Levine (2017). "Randomized Trial of a Hypofractionated Radiation Regimen for the Treatment of Localized Prostate Cancer." Journal of Clinical Oncology 35(17): 1884-1890.

Cho, C. F., L. Yu, T. K. Nsiama, A. N. Kadam, A. Raturi, S. Shukla, G. A. Amadei, N. F. Steinmetz, L. G. Luyt and J. D. Lewis (2017). "Viral nanoparticles decorated with novel EGFL7 ligands enable intravital imaging of tumor neovasculature." Nanoscale 9(33): 12096-12109.

Crump, T., A. Peterson, C. Charbonneau, K. Carlson, J. Sutherland and R. Baverstock (2018). "PT076 - Evaluating the psychometric properties of the EPIC-26." European Urology Supplements 17(2): e1830.

Dadaev, T., E. J. Saunders, P. J. Newcombe, E. Anokian, D. A. Leongamornlert, M. N. Brook, C. et al. (2018). "Fine-mapping of prostate cancer susceptibility loci in a large meta-analysis identifies candidate causal variants." Nature Communications 9(1): 2256.

Eftekhari, R., G. de Lima Stacy, Y. Liu, K. Mihara, M. Saifeddine, F. Noorbakhsh, A. Scarisbrick Isobel and D. Hollenberg Morley (2018). Microenvironment proteinases, proteinase-activated receptor regulation, cancer and inflammation. Biological Chemistry. 399: 1023.

Feifer, A., V. Fradet, D. Drachenberg, G. Gotto, R. A. Rendon, R. Sabbagh, B. Shayegan, B. L. Danielson, R. Casey, A. Zardan, F. Camacho and H. Hew (2017). "Assessment of urologists experience with abiraterone acetate and with a real-world trial: Results obtained from a Canadian Observational Study in Metastatic Cancer of the Prostate (COSMiC)." Journal of Clinical Oncology 35(6\_suppl): 238-238.

Gotto, G., V. Fradet, D. Drachenberg, R. Sabbagh, R. A. Rendon, B. Shayegan, B. L. Danielson, R. Casey, K. Chan, F. Camacho, A. Zardan, H. Hew and A. Feifer (2018). "Real-world evidence in patient-related outcomes (PROs) of metastatic castrate-resistant prostate cancer (mCRPC) patients treated with abiraterone acetate plus prednisone (AA+P)." Journal of Clinical Oncology 36(6\_suppl): 196-196.

Jamaluddin, M. F., S. Ghosh, M. P. Waine, R. S. Sloboda, M. Tavakoli, J. Amanie, A. D. Murtha, D. Yee and N. Usmani (2017). "Quantifying 125I placement accuracy in prostate brachytherapy using postimplant transrectal ultrasound images." Brachytherapy 16(2): 306-312.

Kalra, A. P., J. Xiao, C. Hough, P. Kar, V. Rezania, J. D. Lewis, K. Shankar and J. A. Tuszynski (2018). "Abstract 3195: The molecular mechanism of action and cellular targets of TTFields." Cancer Research 78(13 Supplement): 3195-3195.

Klotz, L., B. Shayegan, C. Guillemette, L. L. Collins, G. Gotto, D. Guérette, M. P. Jammal, T. Pickles, P. O. Richard and F. Saad (2018). Testosterone suppression in the treatment of recurrent or metastatic prostate cancer — A Canadian consensus statement. Can Urol Assoc J. 12: 30-37.

Kryvenko, O. N., S. R. Williamson, K. Trpkov, N. S. Gupta, D. Athanazio, M. K. Selig, P. T. Smith, C. Magi-Galluzzi and M. Jorda (2017). "Small cell-like glandular proliferation of prostate: a rare lesion not related to small cell prostate cancer." Virchows Arch 470(1): 47-54.

McGowan, E. L., D. Fuller, N. Cutumisu, S. North and K. S. Courneya (2017). "The role of the built environment in a randomized controlled trial to increase physical activity among men with prostate cancer: the PROMOTE trial." Supportive Care in Cancer 25(10): 2993-2996.

Palmer TD , e. a. (2018). "Integrin-free tetraspanin CD151 can inhibit tumor cell motility upon clustering and is a clinical indicator of prostate cancer progression. - PubMed - NCBI."

Patel, P., L. Ross, K. Trpkov and G. Gotto (2017). "MP47-16 CURRENT DELAYS FROM BIOPSY TO RADICAL PROSTATECTOMY DO NOT APPEAR TO AFFECT PATHOLOGIC OUTCOMES IN LOW, INTERMEDIATE, OR HIGH-RISK DISEASE." The Journal of Urology 197(4): e634-e635.

Schumacher, F. R., A. A. A. Olama, S. I. Berndt, S. Benlloch, M. Ahmed, E. J. Saunders, T. Dadaev, D. Leongamornlert, E. et al. (2018). "Association analyses of more than 140,000 men identify 63 new prostate cancer susceptibility loci." Nature Genetics 50(7): 928.

Seyednasrollah, F., D. C. Koestler, T. Wang, S. R. Piccolo, R. Vega, R. Greiner, et al. (2017). "A DREAM Challenge to Build Prediction Models for Short-Term Discontinuation of Docetaxel in Metastatic Castration-Resistant Prostate Cancer." JCO Clinical Cancer Informatics(1): 1-15.

Stoletov, K., L. Willetts, R. J. Paproski, D. J. Bond, S. Raha, J. Jovel, B. Adam, A. E. Robertson, F. Wong, E. Woolner, D. L. Sosnowski, T. A. Bismar, G. K.-S. Wong, A. Zijlstra and J. D. Lewis (2018). "Quantitative in vivo whole genome motility screen reveals novel therapeutic targets to block cancer metastasis." Nature Communications 9(1): 2343.

Trpkov, K., S. Sangkhamanon, A. Yilmaz, S. A. C. Medlicott, B. Donnelly, G. Gotto and M. Shea-Budgell (2018). "Concordance of “Case Level” Global, Highest, and Largest Volume Cancer Grade Group on Needle Biopsy Versus Grade Group on Radical Prostatectomy."

Trpkov, K., A. Yilmaz, S. Sangkhamanon, S. Medlicott, B. Donnelly, G. Gotto and M. Shea-Budgell (2018). "Gleason Grading: Clear and Straightforward Rules Facilitate Judgment." The American Journal of Surgical Pathology Publish Ahead of Print.

Vagner, T., C. Spinelli, V. R. Minciacchi, L. Balaj, M. Zandian, A. Conley, A. Zijlstra, M. R. Freeman, F. Demichelis, S. De, E. M. Posadas, H. Tanaka and D. D. Vizio (2018). "Large extracellular vesicles carry most of the tumour DNA circulating in prostate cancer patient plasma." https://doi.org/10.1080/20013078.2018.1505403.

van der Kwast, T. H., J. Helleman, D. Nieboer, S. M. Bruinsma and M. J. Roobol (2018). "Consistent Biopsy Quality and Gleason Grading Within the Global Active Surveillance Global Action Plan 3 Initiative: A Prerequisite for Future Studies." European Urology Oncology.

Vos, L. J., C. K. Ho, B. J. Donnelly, J. D. Reuther and M. Kerba (2018). "A population-based study examining the influence of a specialized rapid-access cancer clinic on initial treatment choice in localized prostate cancer." 12.

Wang, M., R. Pearcey, N. Pervez, D. Yee, A. Mihai, S. Patel, J. Amanie, M. Parliament, A. Murtha, S. Ghosh, M. Mackenzie, C. Field and

N. Usmani (2017). "Clinical outcomes and late toxicity of hypofractionated intensity-modulated radiotherapy for high-risk prostate cancer." Journal of Clinical Oncology 35(6\_suppl): 56-56.